Clinical Trial Update: Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial combining lenvatinib with pembrolizumab in Merkel cell carcinoma is active-not-recruiting, with trial results posted on 2026-04-08.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Merkel Cell Carcinoma
• Neuroendocrine Carcinoma of the Skin
• Trabecular Carcinoma of the Skin

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Merkel Cell Carcinoma, Neuroendocrine Carcinoma of the Skin | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-04-08